DaltonTx, a UK-based technology company, today announces its exit from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster.
AI offers pharma a unique opportunity to discover medicines more effectively and efficiently. However, building adaptive AI platforms requires years of investment in software engineering, coupled with deep understanding of the science and technology. DaltonTx solves this with a disease- and technology-agnostic adaptive platform that plugs directly into pharma, biotech, and CRO workflows, giving teams instant access to AI-enabled discovery instead of spending years developing these capabilities in-house.
DaltonTx is built by scientists for scientists, going beyond predictive modelling to power the full discovery process — from raw data and model training to molecular design, synthesis, and decision-making. DaltonTx isn't just predictive — it's adaptive, a reasoning engine that learns from every scientist, model, and experiment to continuously improve outcomes.
Born from decades of real-world experience, DaltonTx was co-founded by Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE. Together, the team combines drug discovery, machine learning, and software engineering expertise, having built pioneering AI discovery platforms at AstraZeneca and Exscientia and bringing world-leading academic research from the University of Oxford.
Its platform is purpose-built for both small molecules and biologics, making it uniquely suited to support the most complex R&D pipelines. Furthermore, DaltonTx enables collaborative intelligence: scientists can interact with the system, combining their expertise with an engine that iterates and learns, combining human insight and machine learning work together.
With the seed funding from Redalpine, IQ Capital Partners, and Seedcamp, and support from Oxford University Innovation, DaltonTx will redefine how technology can transform drug discovery.
Based in the heart of London's tech and life sciences hub at King's Cross, DaltonTx is positioned at the intersection of engineering, AI, and drug discovery.
